# CURX (Curanex Pharmaceuticals Inc) - SEC EDGAR Financial Statements

> Curanex Pharmaceuticals Inc reported $3.10M in total assets and a net loss of $12.33M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/CURX
- Markdown: https://convexityos.com/fundamentals/CURX.md
- SEC CIK: 0002025942
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:07 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002025942&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$12.43M | Operating profit |
| Net Income | FY 2025 | -$12.33M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$8.13 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $1.58M | Total debt: $542K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Research & Development | $2.99M | -- |
| Total Operating Expenses | $4.24M | $365K |
| **Operating Income** | -$4.24M | -$365K |
| Interest Expense | $8.5K | -- |
| **Net Income** | -$4.23M | -$362K |
| Basic EPS | -$3.40 | -$0.60 |
| **Diluted EPS** | -$3.40 | -$0.60 |
| Basic Shares Outstanding | 1.3M | 663.0K |
| Diluted Shares Outstanding | 1.3M | 663.0K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $1.95M | $2.59M | $2.26M | -- | $677K | -- | -- | -- |
| Total Operating Expenses | $2.83M | $3.33M | $3.18M | $3.09M | $951K | $58K | $137K | -- |
| **Operating Income** | -$2.83M | -$3.33M | -$3.18M | -$3.09M | -$951K | -$58K | -$137K | -- |
| Interest Expense | -- | -- | -- | $0 | $4.1K | $3.1K | $1.4K | -- |
| **Net Income** | -$2.82M | -$3.29M | -$3.15M | -$3.07M | -$954K | -$60K | -$138K | -$146K |
| Basic EPS | -$1.86 | -$2.40 | -$2.20 | -- | -$0.75 | $0.00 | -$0.20 | -- |
| **Diluted EPS** | -$1.86 | -$2.40 | -$2.20 | -- | -$0.75 | $0.00 | -$0.20 | -- |
| Basic Shares Outstanding | 1.5M | 1.4M | 1.4M | -- | 1.3M | 1.2M | 1.2M | -- |
| Diluted Shares Outstanding | 1.5M | 1.4M | 1.4M | -- | 1.3M | 1.2M | 1.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $5.00M | $149K |
| **Cash & Short-Term Investments** | $5.00M | $149K |
| Other Current Assets | -- | $368K |
| **Total Current Assets** | $11.23M | $518K |
| **Total Non-Current Assets** | $353K | $0 |
| **Total Assets** | $11.58M | $518K |
| Accounts Payable | $2.4K | $5.0K |
| **Total Current Liabilities** | $137K | $15K |
| **Total Non-Current Liabilities** | $224K | $0 |
| **Total Liabilities** | $361K | $15K |
| **Total Debt (incl. Leases)** | $347K | -- |
| Common Stock | $142 | $2.4K |
| Retained Earnings | -$4.85M | -$622K |
| **Total Stockholders' Equity** | $11.22M | $503K |
| Total Equity | $11.22M | $503K |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $1.58M | $2.94M | $4.00M | $5.00M | $5.80M | $109K | $149K |
| **Cash & Short-Term Investments** | $1.58M | $2.94M | $4.00M | $5.00M | $5.80M | $109K | $149K |
| Other Current Assets | -- | -- | -- | -- | -- | $596K | $368K |
| **Total Current Assets** | $2.56M | $4.79M | $8.09M | $11.23M | $14.42M | $711K | $518K |
| **Total Non-Current Assets** | $541K | $281K | $318K | $353K | $60K | $76K | $0 |
| **Total Assets** | $3.10M | $5.07M | $8.41M | $11.58M | $14.48M | $787K | $518K |
| Accounts Payable | -- | $154 | $8.4K | $2.4K | $114K | $269 | $5.0K |
| **Total Current Liabilities** | $143K | $104K | $129K | $137K | $186K | $76K | $15K |
| **Total Non-Current Liabilities** | $409K | $182K | $204K | $224K | $0 | $406K | $0 |
| **Total Liabilities** | $552K | $286K | $333K | $361K | $186K | $482K | $15K |
| **Total Debt (incl. Leases)** | $542K | $276K | $311K | $347K | $61K | $76K | -- |
| Common Stock | $157 | $2.8K | $2.8K | $142 | $2.8K | $2.4K | $2.4K |
| Retained Earnings | -$14.10M | -$11.29M | -$8.00M | -$4.85M | -$1.77M | -$820K | -$622K |
| **Total Stockholders' Equity** | $2.55M | $4.79M | $8.08M | $11.22M | $14.29M | $305K | $503K |
| Total Equity | $2.55M | $4.79M | $8.08M | $11.22M | $14.29M | $305K | $503K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Net Income | -$4.23M | -$362K |
| Change in Payables | -$2.6K | $5.0K |
| **Operating Cash Flow** | -$10.48M | -$556K |
| Common Stock Issued | -- | $630K |
| **Financing Cash Flow** | $15.31M | $630K |
| **Net Change in Cash** | $4.82M | $75K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$2.82M | -$3.29M | -$3.15M | -$3.07M | -$954K | -$60K | -$138K | -$146K |
| Stock-Based Compensation | $154K | $0 | $9.8K | -- | -- | -- | -- | -- |
| Change in Payables | -$154 | -$8.2K | $6.0K | -$112K | $114K | -$126K | $121K | -- |
| **Operating Cash Flow** | -$1.36M | -$1.08M | -$955K | -$857K | -$9.19M | -$290K | -$150K | -- |
| **Financing Cash Flow** | -- | -- | -- | $0 | $14.91M | $200K | $200K | -- |
| **Net Change in Cash** | -$1.36M | -$1.08M | -$955K | -$857K | $5.72M | -$90K | $50K | -- |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Return on Equity (ROE) | -37.7% | -71.8% |
| Return on Assets (ROA) | -36.5% | -69.8% |
| Current Ratio | 81.93x | 35.54x |
| Quick Ratio | 36.49x | 10.22x |
| Debt to Equity | 0.03x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -484.4% | -218.7% | -89.6% | -37.7% | -9.1% | -142.4% | -- | -71.8% |
| Return on Assets (ROA) | -398.1% | -206.3% | -86.0% | -36.5% | -9.0% | -55.3% | -- | -69.8% |
| Current Ratio | 17.84x | 45.95x | 62.87x | 81.93x | 77.53x | 9.37x | -- | 35.54x |
| Quick Ratio | 11.02x | 28.17x | 31.07x | 36.49x | 31.19x | 1.43x | -- | 10.22x |
| Debt to Equity | 0.21x | 0.06x | 0.04x | 0.03x | 0.00x | 0.25x | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
